Arvin Dar, PhD
img_Arvin Dar
ADJUNCT PROFESSOR | Pharmacological Sciences
ADJUNCT PROFESSOR | Oncological Sciences
Research Topics
Cancer, Drug Design and Discovery, Enzymology, Genetics, Protein Complexes, Structural Biology
Multi-Disciplinary Training Area
Cancer Biology [CAB], Disease Mechanisms and Therapeutics (DMT)

Through the development and understanding of small molecules, our lab explores links between the regulation of drug targets and the system level properties of biological networks within cells and animals. Our goals are to create new tools to modulate and explore biomolecular function, with a long-term objective of developing innovative medicines for disease. Our work is highly interdisciplinary, employing methods from synthetic organic chemistry, X-ray crystallography, mass spectrometry, informatics, biochemistry and model organism genetics.

In one research area we are investigating one of the most frequently activated pathways in cancer biology: the Ras-Mitogen Activated Protein Kinase (MAPK) pathway. Oncogenic forms of Ras occur in over 20% of all cancers. These mutants have stifled direct pharmacological approaches and inhibitors for the direct effectors of Ras have shown limited or no efficacy in patients. We are exploring new targets or strategies to modulate the Ras pathway through the development of chemical tools. In particular, we are using target-based and systems pharmacology approaches to generate new classes of small molecule modulators for the Ras pathway.

Postdoctoral Fellows: Alex Scopton, Zaigham Khan, Jayasudhan Yerabolu

Current Students:  Jia (Annie) Yu, Ryan Smith, Alexander Real, Arthur Chow

Research Assistant: Lisa Silber

The Dar Laboratory

BSc, University of Western Ontario

PhD, University of Toronto

Postdoctoral Training, University of California, San Francisco


The Mark Foundation for Cancer Research ASPIRE Award

The Mark Foundation for Cancer Research


Friedman Brain Institute Research Scholar

Friedman Brain Institute


Pershing Square Sohn Prize for Young Investigators (PSSCRA)

Pershing Square


Damon Runyon-Rachleff Innovation Award

Damon Runyon Cancer Research Foundation


Pew-Stewart Scholar for Cancer Research

The Pew and Alexander and Margaret Stewart Charitable Trusts


NIH Director’s New Innovator Award

National Institute of Health


UCSF Dean's Postdoctoral Prize



Tisch Cancer Institute Developmental Fund Award


BCRP Multidisciplinary Postdoctoral Award

US Department of Defense


Canadian Graduate Scholarship

Canadian Institutes for Health Research

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Dar during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Company Founder:

  • Nested Therapeutics
  • Prometeo Therapeutics


  • Nested Therapeutics

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Nested Therapeutics

Royalty Payments:

  • Nested Therapeutics

Scientific Advisory Board:

  • Nested Therapeutics

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.